Which has stronger earnings & valuation, AAPG or AUTL?

Ascentage Pharma Group International has higher revenue and earnings than Autolus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 19.43 -$177.71M N/A N/A Autolus Therapeutics $75.39M 5.86 -$287.53M -$1.09 N/A

Does the media favor AAPG or AUTL?

In the previous week, Ascentage Pharma Group International and Ascentage Pharma Group International both had 1 articles in the media. Autolus Therapeutics' average media sentiment score of 0.06 beat Ascentage Pharma Group International's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Autolus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TSHA or AUTL?

In the previous week, Taysha Gene Therapies had 6 more articles in the media than Autolus Therapeutics. MarketBeat recorded 7 mentions for Taysha Gene Therapies and 1 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.06 beat Taysha Gene Therapies' score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Autolus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AUTL or ANAB?

In the previous week, AnaptysBio had 2 more articles in the media than Autolus Therapeutics. MarketBeat recorded 3 mentions for AnaptysBio and 1 mentions for Autolus Therapeutics. AnaptysBio's average media sentiment score of 1.36 beat Autolus Therapeutics' score of 0.06 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AUTL or CMPS?

In the previous week, Compass Pathways had 1 more articles in the media than Autolus Therapeutics. MarketBeat recorded 2 mentions for Compass Pathways and 1 mentions for Autolus Therapeutics. Compass Pathways' average media sentiment score of 0.64 beat Autolus Therapeutics' score of 0.06 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AUTL or AMLX?

In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 1 articles in the media. Autolus Therapeutics' average media sentiment score of 0.06 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Autolus Therapeutics (AUTL) Competitors

$1.66 +0.17 (+11.41%)

Closing price 04:00 PM Eastern

Extended Trading

$1.64 -0.02 (-1.02%)

As of 07:55 PM Eastern

Compare

AUTL vs. AAPG, TSHA, ANAB, CMPS, and AMLX

Should you buy Autolus Therapeutics stock or one of its competitors? MarketBeat compares Autolus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Autolus Therapeutics include Ascentage Pharma Group International (AAPG), Taysha Gene Therapies (TSHA), AnaptysBio (ANAB), Compass Pathways (CMPS), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry.

How does Autolus Therapeutics compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Ascentage Pharma Group International has higher revenue and earnings than Autolus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	19.43	-$177.71M	N/A	N/A
Autolus Therapeutics	$75.39M	5.86	-$287.53M	-$1.09	N/A

In the previous week, Ascentage Pharma Group International and Ascentage Pharma Group International both had 1 articles in the media. Autolus Therapeutics' average media sentiment score of 0.06 beat Ascentage Pharma Group International's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Autolus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascentage Pharma Group International has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

Ascentage Pharma Group International presently has a consensus target price of $46.43, suggesting a potential upside of 171.83%. Autolus Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 427.11%. Given Autolus Therapeutics' higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

72.8% of Autolus Therapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ascentage Pharma Group International has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Ascentage Pharma Group International's return on equity of 0.00% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

Summary

Ascentage Pharma Group International beats Autolus Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Autolus Therapeutics compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Taysha Gene Therapies had 6 more articles in the media than Autolus Therapeutics. MarketBeat recorded 7 mentions for Taysha Gene Therapies and 1 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.06 beat Taysha Gene Therapies' score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Autolus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Taysha Gene Therapies has higher earnings, but lower revenue than Autolus Therapeutics. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	201.77	-$109M	-$0.38	N/A
Autolus Therapeutics	$75.39M	5.86	-$287.53M	-$1.09	N/A

Taysha Gene Therapies presently has a consensus target price of $12.38, indicating a potential upside of 80.53%. Autolus Therapeutics has a consensus target price of $8.75, indicating a potential upside of 427.11%. Given Autolus Therapeutics' higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Taysha Gene Therapies has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Taysha Gene Therapies' return on equity of -56.07% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

Taysha Gene Therapies has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market.

Summary

Taysha Gene Therapies beats Autolus Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to AnaptysBio?

Autolus Therapeutics (NASDAQ:AUTL) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, AnaptysBio had 2 more articles in the media than Autolus Therapeutics. MarketBeat recorded 3 mentions for AnaptysBio and 1 mentions for Autolus Therapeutics. AnaptysBio's average media sentiment score of 1.36 beat Autolus Therapeutics' score of 0.06 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AnaptysBio	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio has higher revenue and earnings than Autolus Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.86	-$287.53M	-$1.09	N/A
AnaptysBio	$234.60M	7.37	-$13.23M	-$1.08	N/A

Autolus Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 427.11%. AnaptysBio has a consensus price target of $81.82, suggesting a potential upside of 37.67%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Autolus Therapeutics is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Autolus Therapeutics has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

AnaptysBio has a net margin of -11.53% compared to Autolus Therapeutics' net margin of -311.98%. Autolus Therapeutics' return on equity of -128.59% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
AnaptysBio	-11.53%	-1,101.24%	-7.75%

72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 33.5% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

AnaptysBio beats Autolus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Compass Pathways?

Autolus Therapeutics (NASDAQ:AUTL) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Autolus Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 2.8% of Compass Pathways shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Compass Pathways has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Compass Pathways' return on equity of -31.07% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Compass Pathways	N/A	-31.07%	-11.40%

Autolus Therapeutics has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.86	-$287.53M	-$1.09	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

Autolus Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 427.11%. Compass Pathways has a consensus price target of $22.90, suggesting a potential upside of 81.03%. Given Autolus Therapeutics' higher probable upside, equities analysts clearly believe Autolus Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Compass Pathways had 1 more articles in the media than Autolus Therapeutics. MarketBeat recorded 2 mentions for Compass Pathways and 1 mentions for Autolus Therapeutics. Compass Pathways' average media sentiment score of 0.64 beat Autolus Therapeutics' score of 0.06 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Pathways beats Autolus Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Autolus Therapeutics compare to Amylyx Pharmaceuticals?

Autolus Therapeutics (NASDAQ:AUTL) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Autolus Therapeutics currently has a consensus target price of $8.75, indicating a potential upside of 427.11%. Amylyx Pharmaceuticals has a consensus target price of $23.00, indicating a potential upside of 40.50%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Autolus Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Amylyx Pharmaceuticals' return on equity of -55.69% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 1 articles in the media. Autolus Therapeutics' average media sentiment score of 0.06 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amylyx Pharmaceuticals has higher revenue and earnings than Autolus Therapeutics. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.86	-$287.53M	-$1.09	N/A
Amylyx Pharmaceuticals	$87.37M	20.83	-$144.74M	-$1.50	N/A

Autolus Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.16, suggesting that its share price is 116% less volatile than the broader market.

Summary

Autolus Therapeutics beats Amylyx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUTL vs. The Competition

Export

Metric	Autolus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$396.57M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-1.52	19.75	24.92	23.97
Price / Sales	5.86	329.42	528.81	109.59
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	2.48	8.29	10.79	6.50
Net Income	-$287.53M	$23.85M	$3.56B	$336.88M
7 Day Performance	11.41%	5.21%	1.67%	-0.22%
1 Month Performance	-2.35%	2.19%	0.43%	0.77%
1 Year Performance	-24.89%	60.99%	32.84%	31.57%

Autolus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUTL Autolus Therapeutics	3.6206 of 5 stars	$1.66 +11.4%	$8.75 +427.1%	-27.3%	$396.57M	$75.39M	N/A	330
AAPG Ascentage Pharma Group International	3.7531 of 5 stars	$17.34 -1.5%	$46.43 +167.8%	-54.2%	$1.64B	$82.10M	N/A	600	Gap Up
TSHA Taysha Gene Therapies	2.7234 of 5 stars	$5.97 +4.6%	$11.64 +94.9%	+165.4%	$1.64B	$9.77M	N/A	180	News Coverage Analyst Forecast High Trading Volume
ANAB AnaptysBio	3.3795 of 5 stars	$59.51 +6.1%	$81.82 +37.5%	+158.9%	$1.63B	$234.60M	N/A	100	Positive News
CMPS Compass Pathways	3.1892 of 5 stars	$11.79 -2.4%	$21.36 +81.2%	+172.8%	$1.63B	N/A	N/A	120	News Coverage Options Volume Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUTL) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Autolus Therapeutics (AUTL) Competitors

AUTL vs. AAPG, TSHA, ANAB, CMPS, and AMLX

How does Autolus Therapeutics compare to Ascentage Pharma Group International?

Summary

How does Autolus Therapeutics compare to Taysha Gene Therapies?

Summary

How does Autolus Therapeutics compare to AnaptysBio?

Summary

How does Autolus Therapeutics compare to Compass Pathways?

Summary

How does Autolus Therapeutics compare to Amylyx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Autolus Therapeutics (AUTL) Competitors

AUTL vs. AAPG, TSHA, ANAB, CMPS, and AMLX

How does Autolus Therapeutics compare to Ascentage Pharma Group International?

Which has stronger earnings & valuation, AAPG or AUTL?

Does the media favor AAPG or AUTL?

Which has more volatility and risk, AAPG or AUTL?

Do analysts recommend AAPG or AUTL?

Do insiders & institutionals hold more shares of AAPG or AUTL?

Is AAPG or AUTL more profitable?

Summary

How does Autolus Therapeutics compare to Taysha Gene Therapies?

Does the media favor TSHA or AUTL?

Which has better valuation & earnings, TSHA or AUTL?

Do analysts rate TSHA or AUTL?

Do institutionals & insiders believe in TSHA or AUTL?

Is TSHA or AUTL more profitable?

Which has more volatility and risk, TSHA or AUTL?

Summary

How does Autolus Therapeutics compare to AnaptysBio?

Does the media refer more to AUTL or ANAB?

Which has stronger valuation and earnings, AUTL or ANAB?

Do analysts prefer AUTL or ANAB?

Which has more volatility and risk, AUTL or ANAB?

Is AUTL or ANAB more profitable?

Do institutionals and insiders hold more shares of AUTL or ANAB?

Summary

How does Autolus Therapeutics compare to Compass Pathways?

Which has more volatility and risk, AUTL or CMPS?

Do institutionals & insiders have more ownership in AUTL or CMPS?

Is AUTL or CMPS more profitable?

Which has higher valuation & earnings, AUTL or CMPS?

Do analysts recommend AUTL or CMPS?

Does the media prefer AUTL or CMPS?

Summary

How does Autolus Therapeutics compare to Amylyx Pharmaceuticals?

Do analysts recommend AUTL or AMLX?

Is AUTL or AMLX more profitable?

Do institutionals and insiders believe in AUTL or AMLX?

Does the media refer more to AUTL or AMLX?

Which has higher earnings and valuation, AUTL or AMLX?

Which has more volatility & risk, AUTL or AMLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools